Racial differences in distribution of fatty acids in prostate cancer and benign prostatic tissues.
Free fatty acid (FFA)
Lipidomics
Prostate cancer (PCa)
Racial disparity
Total fatty acid (TFA)
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
03 Nov 2019
03 Nov 2019
Historique:
received:
15
07
2019
accepted:
03
10
2019
entrez:
4
11
2019
pubmed:
5
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
It remains controversial whether and which fatty acids are different between prostate cancer (PCa) and benign prostatic tissues (BPT) in association with occurrence, progression and racial disparity between African American (AA) and Caucasian American (CA) populations. Total fatty acids (TFA) and free fatty acid (FFA) were determined on fresh frozen prostatic tissues including 26 PCa and 21 BPT from AA and CA patients by Gas chromatography with flame ionization detection (GC-FID) and Electrospray Ionization Mass Spectrometry (ESI-MS), respectively. In all studied population, TFA in 8 out of 16 individual species, in total and in groups of saturated total fatty acid (STFA), mono-unsaturated total fatty acid (MUTFA), poly-unsaturated total fatty acid (PUTFA) and n-6 TFA were significantly higher in PCa than in BPT; FFA in 4 out of 10 individual species, in total and in groups of MUFFA, PUFFA, n-6 FFA and n-3 FFA were significantly higher in PCa than in BPT. The concentrations of most fatty acid parameters correlated with Gleason's grade and clinical stage of PCa. As compared with CA men, AA men had higher concentrations of TFA, especially TFA with chains of 14-18 carbons than in BPT, and lower concentrations of TFA in PCa. Increasing in prostatic fatty acids in the form of TFA and FFA correlated to occurrence, progression and racial disparity of PCa.
Sections du résumé
BACKGROUND
BACKGROUND
It remains controversial whether and which fatty acids are different between prostate cancer (PCa) and benign prostatic tissues (BPT) in association with occurrence, progression and racial disparity between African American (AA) and Caucasian American (CA) populations.
METHODS
METHODS
Total fatty acids (TFA) and free fatty acid (FFA) were determined on fresh frozen prostatic tissues including 26 PCa and 21 BPT from AA and CA patients by Gas chromatography with flame ionization detection (GC-FID) and Electrospray Ionization Mass Spectrometry (ESI-MS), respectively.
RESULTS
RESULTS
In all studied population, TFA in 8 out of 16 individual species, in total and in groups of saturated total fatty acid (STFA), mono-unsaturated total fatty acid (MUTFA), poly-unsaturated total fatty acid (PUTFA) and n-6 TFA were significantly higher in PCa than in BPT; FFA in 4 out of 10 individual species, in total and in groups of MUFFA, PUFFA, n-6 FFA and n-3 FFA were significantly higher in PCa than in BPT. The concentrations of most fatty acid parameters correlated with Gleason's grade and clinical stage of PCa. As compared with CA men, AA men had higher concentrations of TFA, especially TFA with chains of 14-18 carbons than in BPT, and lower concentrations of TFA in PCa.
CONCLUSIONS
CONCLUSIONS
Increasing in prostatic fatty acids in the form of TFA and FFA correlated to occurrence, progression and racial disparity of PCa.
Identifiants
pubmed: 31677641
doi: 10.1186/s12944-019-1130-4
pii: 10.1186/s12944-019-1130-4
pmc: PMC6825718
doi:
Substances chimiques
Fatty Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103418
Pays : United States
Références
Cancer Causes Control. 2000 Aug;11(7):609-15
pubmed: 10977105
Br J Nutr. 2010 May;103(9):1375-80
pubmed: 20082736
Urology. 2009 May;73(5 Suppl):S4-10
pubmed: 19375626
Urology. 2000 Feb;55(2):246-51
pubmed: 10688088
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
J Natl Cancer Inst. 2014 Apr;106(4):dju017
pubmed: 24685921
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
pubmed: 10200776
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016
pubmed: 28922023
PLoS One. 2012;7(11):e48889
pubmed: 23152813
BJU Int. 2003 Oct;92(6):551-4
pubmed: 14511031
Prostate Cancer Prostatic Dis. 2006;9(3):230-4
pubmed: 16683009
Prog Lipid Res. 2013 Apr;52(2):220-30
pubmed: 23376124
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Cell Metab. 2014 Mar 4;19(3):393-406
pubmed: 24606897
Nutrients. 2014 Dec 22;6(12):6095-109
pubmed: 25533015
Am J Clin Nutr. 2012 Dec;96(6):1354-61
pubmed: 23134890
Cancer Prev Res (Phila). 2014 Jul;7(7):766-76
pubmed: 24824038
Am J Clin Nutr. 2000 Jan;71(1 Suppl):179S-88S
pubmed: 10617969
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
Am J Clin Nutr. 2001 Apr;73(4):815-20
pubmed: 11273858
Urology. 2011 Jul;78(1):110-5
pubmed: 21397300
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1422-8
pubmed: 14693732
Cancer. 2006 Feb 15;106(4):789-95
pubmed: 16400651
BMJ. 2016 Nov 23;355:i5796
pubmed: 27881409
J Nutr. 2004 Dec;134(12 Suppl):3412S-3420S
pubmed: 15570047
Urol Oncol. 2013 Apr;31(3):318-24
pubmed: 21414816
J Urol. 2007 Dec;178(6):2391-6; discussion 2396
pubmed: 17936811
J Natl Cancer Inst. 2013 Aug 7;105(15):1132-41
pubmed: 23843441
J Urol. 2000 Dec;164(6):2168-72
pubmed: 11061949
Mol Neurobiol. 2013 Oct;48(2):353-62
pubmed: 23813102
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
pubmed: 20647400
Prostate. 2011 Jun 15;71(9):985-97
pubmed: 21541975
Cancer Res. 2001 Aug 15;61(16):5974-8
pubmed: 11507037
Clin Cancer Res. 2009 Apr 1;15(7):2559-66
pubmed: 19318492
Cancer Res. 2006 Jun 15;66(12):5977-80
pubmed: 16778164
Phytochemistry. 2006 Sep;67(17):1907-24
pubmed: 16843506
Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):335-8
pubmed: 10750674
Can Urol Assoc J. 2013 May-Jun;7(5-6):E333-43
pubmed: 23766835
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14
pubmed: 15184677
Clin Biochem. 1999 Aug;32(6):405-9
pubmed: 10667474
J Clin Oncol. 2004 Feb 1;22(3):439-45
pubmed: 14691120
BMC Urol. 2014 Dec 11;14:98
pubmed: 25495177
Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):115-9
pubmed: 8850272
Am J Epidemiol. 2011 Jun 15;173(12):1429-39
pubmed: 21518693
Cancer. 2004 Dec 15;101(12):2744-54
pubmed: 15495177
Urology. 2009 Jul;74(1):185-90
pubmed: 19428088
Exp Physiol. 1991 May;76(3):445-55
pubmed: 1878200
Am J Clin Nutr. 2008 Nov;88(5):1353-63
pubmed: 18996872
Cancer. 1999 Sep 15;86(6):1019-27
pubmed: 10491529
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cancer Causes Control. 2012 Jan;23(1):23-33
pubmed: 21984307
Am J Epidemiol. 2013 Oct 15;178(8):1246-55
pubmed: 23989197
Nutr Metab Cardiovasc Dis. 2010 May;20(4):284-94
pubmed: 20303720
BJU Int. 2006 Feb;97(2):270-3
pubmed: 16430627
Int J Cancer. 2013 Oct 15;133(8):1882-91
pubmed: 23575905
Cancer Causes Control. 2009 Mar;20(2):211-23
pubmed: 18821021
Am J Clin Nutr. 2004 Jul;80(1):204-16
pubmed: 15213050
Food Chem Toxicol. 2007 Apr;45(4):517-29
pubmed: 17141389
Prostate. 2016 Sep;76(13):1182-91
pubmed: 27197070